IDEXX Laboratories, Inc. $IDXX Shares Sold by Swiss National Bank

Swiss National Bank reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 231,900 shares of the company’s stock after selling 13,400 shares during the period. Swiss National Bank owned approximately 0.29% of IDEXX Laboratories worth $148,159,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Blalock Williams LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $590,000. New York State Common Retirement Fund grew its position in IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after buying an additional 3,820 shares during the period. Mediolanum International Funds Ltd grew its position in IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after buying an additional 4,909 shares during the period. Principal Financial Group Inc. increased its holdings in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after buying an additional 187,967 shares in the last quarter. Finally, Orion Porfolio Solutions LLC increased its holdings in IDEXX Laboratories by 116.6% in the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock valued at $5,749,000 after buying an additional 5,770 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IDXX shares. UBS Group reduced their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. BTIG Research dropped their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Piper Sandler decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Finally, Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $610.45 on Tuesday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The firm has a market cap of $48.60 billion, a price-to-earnings ratio of 46.71, a price-to-earnings-growth ratio of 3.69 and a beta of 1.66. The company’s 50-day moving average is $665.39 and its two-hundred day moving average is $668.46. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 45,957 shares of company stock valued at $29,862,109 in the last 90 days. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.